Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009

Keizo Yamaguchi; Yoshikazu Ishii; Morihiro Iwata; Naoki Watanabe; Masaaki Shinagawa; Minoru Yasujima; Akira Suwabe; Makiko Kuroda; Mitsuo Kaku; Miho Kitagawa; Keiji Kanemitsu; Yuji Imafuku; Masami Murakami; Sachie Yomoda; Nobuyuki Taniguchi; Toshiyuki Yamada; Fumio Nomura; Harushige Kanno; Shigefumi Maesaki; Giichi Hashikita; Shigemi Kondo; Shigeki Misawa; Hajime Horiuchi; Yoko Tazawa; Hideki Nakashima; Hiromu Takemura; Masahiko Okada; Yoshinori Horikawa; Masato Maekawa; Osanori Nagura; Tetsuya Yagi; Hisashi Baba; Shiomi Ishigo; Naohisa Fujita; Toshiaki Komori; Satoshi Ichiyama; Kiyoharu Yamanaka; Yoko Murata; Shuji Matsuo; Hisashi Kohno; Seiji Kawano; Shohiro Kinoshita; Tomohiko Taminato; Kiyoshi Negayama; Mitsuharu Murase; Hitoshi Miyamoto; Nobuchika Kusano; Motoko Nose; Michiya Yokozaki; Hideyuki Itaha; Akira Matsunaga; Hisae Yoshimura; Shigeru Kohno; Katsunori Yanagihara; Junichi Matsuda; Tetsunori Saikawa; Kazufumi Hiramatsu

Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009

Keizo Yamaguchi, Yoshikazu Ishii, Morihiro Iwata, Naoki Watanabe, Masaaki Shinagawa, Minoru Yasujima, Akira Suwabe, Makiko Kuroda, Mitsuo Kaku, Miho Kitagawa, Keiji Kanemitsu, Yuji Imafuku, Masami Murakami, Sachie Yomoda, Nobuyuki Taniguchi, Toshiyuki Yamada, Fumio Nomura, Harushige Kanno, Shigefumi Maesaki, Giichi HashikitaShigemi Kondo, Shigeki Misawa, Hajime Horiuchi, Yoko Tazawa, Hideki Nakashima, Hiromu Takemura, Masahiko Okada, Yoshinori Horikawa, Masato Maekawa, Osanori Nagura, Tetsuya Yagi, Hisashi Baba, Shiomi Ishigo, Naohisa Fujita, Toshiaki Komori, Satoshi Ichiyama, Kiyoharu Yamanaka, Yoko Murata, Shuji Matsuo, Hisashi Kohno, Seiji Kawano, Shohiro Kinoshita, Tomohiko Taminato, Kiyoshi Negayama, Mitsuharu Murase, Hitoshi Miyamoto, Nobuchika Kusano, Motoko Nose, Michiya Yokozaki, Hideyuki Itaha, Akira Matsunaga, Hisae Yoshimura, Shigeru Kohno, Katsunori Yanagihara, Junichi Matsuda, Tetsunori Saikawa, Kazufumi Hiramatsu

University Hospital

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 2655 strains including 810 strains of Gram-positive bacteria, 1635 strains of Gram-negative bacteria, and 210 strains of anaerobic bacteria obtained from 30 medical institutions during 2009 was examined. The results were as follows; 1. MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA). 2. MEPM maintained potent and stable antibacterial activity against Pesudomonas aeruginosa. The proportion of MEPM-resistant strains to ciprofloxacin-resistant strains or imipenem-resistant strains were 53.1% and 58.0% respectively. 3. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1% (26 strains) in enterobacteriaceae. And the proportion of metallo-β-lactamase strains was 2.0% (6 strains) in P. aeruginosa. 4. Of all species tested, there were no species except for Bacteroides fragilis group, which MIC₉₀ of MEPM was more than 4-fold higher than those in our previous study. Therefore, there is almost no significant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem for serious infections treatment at present, 14 years passed after available for commercial use in Japan.

Original language	English
Pages (from-to)	53-95
Number of pages	43
Journal	Japanese Journal of Antibiotics
Volume	64
Issue number	2
Publication status	Published - Apr 2011

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Yamaguchi, K., Ishii, Y., Iwata, M., Watanabe, N., Shinagawa, M., Yasujima, M., Suwabe, A., Kuroda, M., Kaku, M., Kitagawa, M., Kanemitsu, K., Imafuku, Y., Murakami, M., Yomoda, S., Taniguchi, N., Yamada, T., Nomura, F., Kanno, H., Maesaki, S., ... Hiramatsu, K. (2011). Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009. Japanese Journal of Antibiotics, 64(2), 53-95.

Yamaguchi, K, Ishii, Y, Iwata, M, Watanabe, N, Shinagawa, M, Yasujima, M, Suwabe, A, Kuroda, M, Kaku, M, Kitagawa, M, Kanemitsu, K, Imafuku, Y, Murakami, M, Yomoda, S, Taniguchi, N, Yamada, T, Nomura, F, Kanno, H, Maesaki, S, Hashikita, G, Kondo, S, Misawa, S, Horiuchi, H, Tazawa, Y, Nakashima, H, Takemura, H, Okada, M, Horikawa, Y, Maekawa, M, Nagura, O, Yagi, T, Baba, H, Ishigo, S, Fujita, N, Komori, T, Ichiyama, S, Yamanaka, K, Murata, Y, Matsuo, S, Kohno, H, Kawano, S, Kinoshita, S, Taminato, T, Negayama, K, Murase, M, Miyamoto, H, Kusano, N, Nose, M, Yokozaki, M, Itaha, H, Matsunaga, A, Yoshimura, H, Kohno, S, Yanagihara, K, Matsuda, J, Saikawa, T & Hiramatsu, K 2011, 'Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009', Japanese Journal of Antibiotics, vol. 64, no. 2, pp. 53-95.

@article{42aafb87b6134617a44806194b570dfd,

title = "Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009",

abstract = "The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 2655 strains including 810 strains of Gram-positive bacteria, 1635 strains of Gram-negative bacteria, and 210 strains of anaerobic bacteria obtained from 30 medical institutions during 2009 was examined. The results were as follows; 1. MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA). 2. MEPM maintained potent and stable antibacterial activity against Pesudomonas aeruginosa. The proportion of MEPM-resistant strains to ciprofloxacin-resistant strains or imipenem-resistant strains were 53.1% and 58.0% respectively. 3. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1% (26 strains) in enterobacteriaceae. And the proportion of metallo-β-lactamase strains was 2.0% (6 strains) in P. aeruginosa. 4. Of all species tested, there were no species except for Bacteroides fragilis group, which MIC90 of MEPM was more than 4-fold higher than those in our previous study. Therefore, there is almost no significant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem for serious infections treatment at present, 14 years passed after available for commercial use in Japan.",

author = "Keizo Yamaguchi and Yoshikazu Ishii and Morihiro Iwata and Naoki Watanabe and Masaaki Shinagawa and Minoru Yasujima and Akira Suwabe and Makiko Kuroda and Mitsuo Kaku and Miho Kitagawa and Keiji Kanemitsu and Yuji Imafuku and Masami Murakami and Sachie Yomoda and Nobuyuki Taniguchi and Toshiyuki Yamada and Fumio Nomura and Harushige Kanno and Shigefumi Maesaki and Giichi Hashikita and Shigemi Kondo and Shigeki Misawa and Hajime Horiuchi and Yoko Tazawa and Hideki Nakashima and Hiromu Takemura and Masahiko Okada and Yoshinori Horikawa and Masato Maekawa and Osanori Nagura and Tetsuya Yagi and Hisashi Baba and Shiomi Ishigo and Naohisa Fujita and Toshiaki Komori and Satoshi Ichiyama and Kiyoharu Yamanaka and Yoko Murata and Shuji Matsuo and Hisashi Kohno and Seiji Kawano and Shohiro Kinoshita and Tomohiko Taminato and Kiyoshi Negayama and Mitsuharu Murase and Hitoshi Miyamoto and Nobuchika Kusano and Motoko Nose and Michiya Yokozaki and Hideyuki Itaha and Akira Matsunaga and Hisae Yoshimura and Shigeru Kohno and Katsunori Yanagihara and Junichi Matsuda and Tetsunori Saikawa and Kazufumi Hiramatsu",

year = "2011",

month = apr,

language = "English",

volume = "64",

pages = "53--95",

journal = "Japanese Journal of Antibiotics",

issn = "0368-2781",

publisher = "Japan Antibiotics Research Association",

number = "2",

}

TY - JOUR

T1 - Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009

AU - Yamaguchi, Keizo

AU - Ishii, Yoshikazu

AU - Iwata, Morihiro

AU - Watanabe, Naoki

AU - Shinagawa, Masaaki

AU - Yasujima, Minoru

AU - Suwabe, Akira

AU - Kuroda, Makiko

AU - Kaku, Mitsuo

AU - Kitagawa, Miho

AU - Kanemitsu, Keiji

AU - Imafuku, Yuji

AU - Murakami, Masami

AU - Yomoda, Sachie

AU - Taniguchi, Nobuyuki

AU - Yamada, Toshiyuki

AU - Nomura, Fumio

AU - Kanno, Harushige

AU - Maesaki, Shigefumi

AU - Hashikita, Giichi

AU - Kondo, Shigemi

AU - Misawa, Shigeki

AU - Horiuchi, Hajime

AU - Tazawa, Yoko

AU - Nakashima, Hideki

AU - Takemura, Hiromu

AU - Okada, Masahiko

AU - Horikawa, Yoshinori

AU - Maekawa, Masato

AU - Nagura, Osanori

AU - Yagi, Tetsuya

AU - Baba, Hisashi

AU - Ishigo, Shiomi

AU - Fujita, Naohisa

AU - Komori, Toshiaki

AU - Ichiyama, Satoshi

AU - Yamanaka, Kiyoharu

AU - Murata, Yoko

AU - Matsuo, Shuji

AU - Kohno, Hisashi

AU - Kawano, Seiji

AU - Kinoshita, Shohiro

AU - Taminato, Tomohiko

AU - Negayama, Kiyoshi

AU - Murase, Mitsuharu

AU - Miyamoto, Hitoshi

AU - Kusano, Nobuchika

AU - Nose, Motoko

AU - Yokozaki, Michiya

AU - Itaha, Hideyuki

AU - Matsunaga, Akira

AU - Yoshimura, Hisae

AU - Kohno, Shigeru

AU - Yanagihara, Katsunori

AU - Matsuda, Junichi

AU - Saikawa, Tetsunori

AU - Hiramatsu, Kazufumi

PY - 2011/4

Y1 - 2011/4

N2 - The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 2655 strains including 810 strains of Gram-positive bacteria, 1635 strains of Gram-negative bacteria, and 210 strains of anaerobic bacteria obtained from 30 medical institutions during 2009 was examined. The results were as follows; 1. MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA). 2. MEPM maintained potent and stable antibacterial activity against Pesudomonas aeruginosa. The proportion of MEPM-resistant strains to ciprofloxacin-resistant strains or imipenem-resistant strains were 53.1% and 58.0% respectively. 3. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1% (26 strains) in enterobacteriaceae. And the proportion of metallo-β-lactamase strains was 2.0% (6 strains) in P. aeruginosa. 4. Of all species tested, there were no species except for Bacteroides fragilis group, which MIC90 of MEPM was more than 4-fold higher than those in our previous study. Therefore, there is almost no significant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem for serious infections treatment at present, 14 years passed after available for commercial use in Japan.

AB - The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 2655 strains including 810 strains of Gram-positive bacteria, 1635 strains of Gram-negative bacteria, and 210 strains of anaerobic bacteria obtained from 30 medical institutions during 2009 was examined. The results were as follows; 1. MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA). 2. MEPM maintained potent and stable antibacterial activity against Pesudomonas aeruginosa. The proportion of MEPM-resistant strains to ciprofloxacin-resistant strains or imipenem-resistant strains were 53.1% and 58.0% respectively. 3. The proportion of extended-spectrum β-lactamase (ESBL) strains was 3.1% (26 strains) in enterobacteriaceae. And the proportion of metallo-β-lactamase strains was 2.0% (6 strains) in P. aeruginosa. 4. Of all species tested, there were no species except for Bacteroides fragilis group, which MIC90 of MEPM was more than 4-fold higher than those in our previous study. Therefore, there is almost no significant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem for serious infections treatment at present, 14 years passed after available for commercial use in Japan.

UR - http://www.scopus.com/inward/record.url?scp=79957442373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957442373&partnerID=8YFLogxK

M3 - Article

C2 - 21721247

AN - SCOPUS:79957442373

SN - 0368-2781

VL - 64

SP - 53

EP - 95

JO - Japanese Journal of Antibiotics

JF - Japanese Journal of Antibiotics

IS - 2

ER -

Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this